Pure Global AI
NCT06304844Not yet recruiting

Risk of CKD in Diabetic Patients With MAFLD

Assessing the Risk of Chronic Kidney Disease Associated With Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus
Sohag UniversityClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Type 2 Diabetes
Drug/Device/Intervention
transient elastography (Fibroscan)
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Sohag University
Timeline & enrollment
Phase
N/A
Start date
Apr 20, 2024
End date
Feb 01, 2025
Enrollment
300 participants
Primary outcome

Determine the number of participant with eGFR60 ml/min/1.73 m2 or albuminuria (urinary albumin-to-creatinine ratio (ACR) ⩾3 mg/mmol) in patients with type 2 DM and MAFLD

Summary

This cross-sectional study of 300 participants investigates the risk of chronic kidney
 disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease
 (MAFLD) and type 2 diabetes. By evaluating hepatic measurements and metabolic markers, the
 study aims to identify key risk factors for CKD in this population, contributing valuable
 insights to inform targeted interventions.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06304844
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06304844 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Not yet recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.